UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 211

Sortiert nach

Editorial: symptoms predicting active intestinal inflammation in patients with IBD

Alimentary pharmacology & therapeutics, 2023-01, Vol.57 (1), p.165-166

Mantzaris, Gerassimos J.

2023

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract

World journal of gastroenterology : WJG, 2020-08, Vol.26 (31), p.4579-4588

2020

Link zum Volltext

Verfügbarkeit prüfen

Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis

Alimentary pharmacology & therapeutics, 2022-08, Vol.56 (4), p.735-736

2022

Link zum Volltext

Verfügbarkeit prüfen

Letter: towards gender‐stratified colorectal cancer screening and surveillance?

Alimentary pharmacology & therapeutics, 2022-02, Vol.55 (4), p.504-505

2022

Link zum Volltext

Verfügbarkeit prüfen

Molecular basis of vitamin D action in inflammatory bowel disease

Autoimmunity reviews, 2022-08, Vol.21 (8), p.103136, Article 103136

2022

Link zum Volltext

Verfügbarkeit prüfen

Helicobacter pylori infection and inflammatory bowel disease: Is there a link?

World journal of gastroenterology : WJG, 2014-06, Vol.20 (21), p.6374-6385

2014

Link zum Volltext

Verfügbarkeit prüfen

Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trials—a missing link

Alimentary pharmacology & therapeutics, 2021-03, Vol.53 (6), p.749-750

2021

Link zum Volltext

Verfügbarkeit prüfen

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

The New England journal of medicine, 2010-04, Vol.362 (15), p.1383-1395

2010

Link zum Volltext

Verfügbarkeit prüfen

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

Journal of Crohn's & colitis, 2010-02, Vol.4 (1), p.7-27

2010

Link zum Volltext

Verfügbarkeit prüfen

Management of the Elderly Inflammatory Bowel Disease Patient

Digestion, 2020-09, Vol.101 (Suppl 1), p.105-119

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

Gut, 2014-01, Vol.63 (1), p.88-95

2014

Link zum Volltext

Verfügbarkeit prüfen

DNA methylation profile of genes involved in inflammation and autoimmunity in inflammatory bowel disease

Medicine (Baltimore), 2014-12, Vol.93 (28), p.e309-e309

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of IL12/23 Blockade Expands Our Therapeutic Targets and Challenges the Old Dogma in Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.1836-1837

2020

Link zum Volltext

Verfügbarkeit prüfen

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis

Journal of Crohn's & colitis, 2012-12, Vol.6 (10), p.965-990

2012

Link zum Volltext

Verfügbarkeit prüfen

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update

Journal of Crohn's and colitis, 2017-01, Vol.11 (1), p.26-34

2017

Link zum Volltext

Verfügbarkeit prüfen

Circulating MicroRNA in inflammatory bowel disease

Journal of Crohn's and colitis, 2012-10, Vol.6 (9), p.900-904

2012

Link zum Volltext

Verfügbarkeit prüfen

Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

Journal of Crohn's and colitis, 2021-10, Vol.15 (10), p.1694-1706

2021

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study

European journal of gastroenterology & hepatology, 2024-03, Vol.36 (3), p.281

2024

Link zum Volltext

Verfügbarkeit prüfen

S869 Real World Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-Naïve Patients With Crohn’s Disease: Results From the EVOLVE Study

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e627-e628

2022

Link zum Volltext

Verfügbarkeit prüfen

Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases

Gastroenterology (New York, N.Y. 1943), 2019-10, Vol.157 (4), p.1032-1043.e1

2019

Link zum Volltext

Verfügbarkeit prüfen

The Greek Response to COVID-19: A True Success Story from an IBD Perspective

Inflammatory bowel diseases, 2020-07, Vol.26 (8), p.1144-1148

2020

Link zum Volltext

Verfügbarkeit prüfen

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

Journal of Crohn's & colitis, 2012-12, Vol.6 (10), p.991-1030

2012

Link zum Volltext

Verfügbarkeit prüfen

Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial

Clinical gastroenterology and hepatology, 2024-02, Vol.22 (2), p.347-356.e6

2024

Link zum Volltext

Verfügbarkeit prüfen

Anti-TNFs: Originators and Biosimilars

Digestive diseases (Basel), 2016-01, Vol.34 (1-2), p.132-139

Mantzaris, Gerassimos J.

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 211

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Englisch
(211)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Editorial: symptoms predicting active intestinal inflammation in patients with IBD

COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract

Editorial: golimumab thresholds to achieve stringent medium‐ and long‐term therapeutic outcomes in patients with ulcerative colitis

Letter: towards gender‐stratified colorectal cancer screening and surveillance?

Molecular basis of vitamin D action in inflammatory bowel disease

Helicobacter pylori infection and inflammatory bowel disease: Is there a link?

Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trials—a missing link

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

Management of the Elderly Inflammatory Bowel Disease Patient

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

DNA methylation profile of genes involved in inflammation and autoimmunity in inflammatory bowel disease

Efficacy of IL12/23 Blockade Expands Our Therapeutic Targets and Challenges the Old Dogma in Ulcerative Colitis

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis

A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates

ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update

Circulating MicroRNA in inflammatory bowel disease

Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study

Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study

S869 Real World Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-Naïve Patients With Crohn’s Disease: Results From the EVOLVE Study

Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases

The Greek Response to COVID-19: A True Success Story from an IBD Perspective

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial

Anti-TNFs: Originators and Biosimilars

Suchergebnisse filtern